Reklama
powiązane z: treatment of prostate cancerAssess your risk for prostate cancer with MPS2 - you may avoid unnecessary biopsy. Introducing the next generation of prostate cancer risk screening.
Search results
14 cze 2024 · Learn about the tests, procedures and options for diagnosing and treating prostate cancer. Find out how factors such as grade, stage and aggressiveness affect your treatment choices.
16 lut 2023 · Prostate cancer treatment can include active surveillance, surgery, radiation therapy, hormonal therapy, chemotherapy, immunotherapy, and supportive care. Learn more about treatment options for prostate cancer in this expert-reviewed summary.
Learn about the different treatment options for prostate cancer based on the stage and risk group of the cancer. Find out how factors such as age, health, and preferences can affect your treatment choices.
Learn about the different treatment options for prostate cancer, such as surgery, radiation, hormone therapy, and more. Find out how to make informed decisions, get support, and access clinical trials and complementary methods.
21 mar 2023 · ADT–docetaxel–abiraterone–prednisone is recommended as first-line treatment for fit men with de novo metastatic hormone-sensitive prostate cancer (mHSPC), especially in those with multiple bone metastases (>3) or visceral metastases [I, B; European Society for Medical Oncology-Magnitude of Clinical Benefit Scale (ESMO-MCBS) v1.1 score: 4 ...
This review summarizes advances in risk classification methods, imaging techniques, biomarkers for diagnosis, and treatments for prostate cancer.
25 cze 2020 · Key treatment recommendations are provided. •. Recommendations have been updated in the light of new evidence. Key words. chemotherapy. hormone therapy. prostate cancer. radiotherapy. surgery. Screening and early detection. Subclinical prostate cancer is common in men >50 years.
Reklama
powiązane z: treatment of prostate cancerAssess your risk for prostate cancer with MPS2 - you may avoid unnecessary biopsy. Introducing the next generation of prostate cancer risk screening.